glp 1 fgf21 agonist boehringer Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Media Centre | EASD
Description
J.LouJ.LokurkarI.et al (2014)
Research Evidence Comparison# Orforglipron# The ATTAIN program includes ATTAIN-1 (obesity, 12.4% weight loss at 36 mg, 72 weeks, published in NEJM), ATTAIN-2 (obesity + T2D, 10.5% weight loss), and ATTAIN-MAINTAIN (weight maintenance after injectable switch)
Barzilai, N
Drug: Semaglutide, Exenatide, and Liraglutide are the leading drugs in this market, with semaglutide particularly standing out due to its proven efficacy in both diabetes and obesity treatment
Theyve undergone extensive clinical trials proving their safety and efficacy
